Institute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia.
Department of Probability and Statistics, Faculty of Mathematics, University of Belgrade, Belgrade, Serbia.
Rheumatol Int. 2019 Sep;39(9):1595-1605. doi: 10.1007/s00296-019-04376-8. Epub 2019 Jul 15.
To assess prevalence and change of depression/anxiety symptoms in spondyloarthritis patients and feasibility of depression/anxiety questionnaires. 43 Patients with axial spondyloarthritis (axSpA) and 27 patients with psoriatic arthritis (PsA) were consecutively recruited. There were 34 patients on biologics and 36 patients on nonbiologics. Patients were not previously treated for depression. The demographic variables, pain, patient global assessment, laboratory, clinical findings, diseases activity scores, Beck Depression Inventory (BDI) and Depression Anxiety and Stress Scale-short version (DASS-21) were collected. The study visits were at the beginning, after 1 month, after 3 and after 6 months. In axSpA and PsA patients on biologics, BDI and DASS-21 were significantly lower compared to nonbiologics group during time. The axSpA patients on biologics had significantly lower BDI and depression severity by BDI at each time point and lower DASS-21 after 1, 3 and 6 months. BDI in PsA patients who received biological therapy was significantly lower after 3 and 6 months. In biologics groups, BDI significantly decreased after 3 months in axSpA patients and after 1 month in PsA patients. In axSpA patients, there was a medium correlation between BDI and axial pain, patient global assessment and disease activity scores. The biological therapy significantly affected the depression/anxiety symptoms in axSpA and PsA during time. BDI moderately correlated with pain and disease activity in axSpA. BDI and DASS-21 are easy to use in daily practice.
评估强直性脊柱炎（axSpA）和银屑病关节炎（PsA）患者抑郁/焦虑症状的发生率和变化，以及抑郁/焦虑问卷的可行性。连续招募了 43 例 axSpA 患者和 27 例 PsA 患者。其中 34 例患者接受生物治疗，36 例患者接受非生物治疗。患者之前未接受过抗抑郁治疗。收集了人口统计学变量、疼痛、患者总体评估、实验室、临床发现、疾病活动评分、贝克抑郁量表（BDI）和抑郁焦虑和压力量表-短版（DASS-21）。研究访问在开始时、1 个月后、3 个月后和 6 个月后进行。在 axSpA 和接受生物治疗的 PsA 患者中，BDI 和 DASS-21 在整个时间内均明显低于非生物治疗组。axSpA 接受生物治疗的患者在每个时间点的 BDI 和抑郁严重程度均显著低于生物治疗组，并且在 1、3 和 6 个月后 DASS-21 显著降低。接受生物治疗的 PsA 患者在 3 个月和 6 个月后 BDI 显著降低。在生物治疗组中，axSpA 患者在 3 个月后 BDI 显著降低，PsA 患者在 1 个月后 BDI 显著降低。在 axSpA 患者中，BDI 与轴向疼痛、患者总体评估和疾病活动评分之间存在中等相关性。生物治疗在整个时间内显著影响 axSpA 和 PsA 的抑郁/焦虑症状。BDI 与 axSpA 中的疼痛和疾病活动中度相关。BDI 和 DASS-21 在日常实践中易于使用。
